HSD17B1 and cancer: Molecular docking, molecular dynamic simulation (MDS), and pharmacokinetic studies were done to evaluate β-sitosterol (Fig. 7 compound 38) and OA as anti-cancer agents by inhibiting human estrogenic 17 beta-hydroxysteroid dehydrogenase type-1 (HSD17B1.